OnCo

Edge

The freshest signals in cancer: new papers, trial results, approvals and law, updated with every build.

This week in numbers

Items dated to a day in the last seven days, across every source; dates known only to the month or year are not counted.

Latest

Ranked newest first, with approvals, withdrawals and phase 3 results counting as two weeks fresher than their date, other results, law and papers in the leading journals one week fresher, and preprints one week older; every kind keeps its most recent items so no filter is empty while its source has data. Within a day the weightier items come first. Pick types to combine them; For you narrows to the cancer chosen in For me (a choice that stays in this browser); the first filter reads the full 500-item feed.

For you

200 items on this page.

1

  1. Issue· OnCo weekly issue

    OnCo weekly, 2026-09-24

    519 changelog entries, 1 regulatory event, 1 upcoming date.

1

  1. Issue· OnCo weekly issue

    OnCo weekly, 2026-09-23

    491 changelog entries, 1 regulatory event, 1 upcoming date, 2 corrections.

18

  1. Paper· Nat Med

    Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study.

    Published in Nat Med on 22 September 2026; found by the roadmap watch for PATHFINDER 2.

  2. Issue· OnCo weekly issue

    OnCo weekly, 2026-09-22

    451 changelog entries, 1 regulatory event, 2 upcoming dates, 2 corrections.

  3. Paper· J Pediatr Endocrinol Metab

    Successful management of paediatric chronic SIAD with oral urea: report of two cases.

    Published in J Pediatr Endocrinol Metab on 22 September 2026; matched the OnCo record for Paediatric low-grade glioma.

  4. Preprint· bioRxiv

    A Dynamically Regulated Designed IL-2 for Tumor- localized Signaling

    Posted on bioRxiv on 22 September 2026; not peer reviewed; matched CAR-T cell therapy and Aldesleukin.

  5. Preprint· bioRxiv

    A fibroblast-rich transcriptomic axis reflects stromal remodeling within the CMS4 phenotype in colorectal cancer

    Posted on bioRxiv on 22 September 2026; not peer reviewed; matched Single-cell & spatial profiling.

  6. Preprint· bioRxiv

    A Rationally Designed Transgene Drives CAR T Functional Persistence and Durable Regression of Solid Tumors

    Posted on bioRxiv on 22 September 2026; not peer reviewed; matched CAR-T cell therapy and Aldesleukin.

  7. Preprint· bioRxiv

    Alcohol Promotes ER+ Breast Cancer Cell Proliferation and Invasion Through the Upregulation of Neuregulin 1-Mediated ER-ErbB3 Crosstalk

    Posted on bioRxiv on 22 September 2026; not peer reviewed; matched Fulvestrant, HER3 and AKT.

  8. Preprint· bioRxiv

    An integrated, transcript-resolution atlas of prostate cancer progression unmasks associations with oncogenic pathways

    Posted on bioRxiv on 22 September 2026; not peer reviewed; matched RNA sequencing & expression profiling, BRCA1 / BRCA2 and Long-read sequencing.

  9. Preprint· Research Square

    An Outcome-Independent Analytical Framework Reveals Systemic Discordance Between a Continuous Neural-Mesenchymal Programme and Consensus Molecular Subtyping in Colorectal Cancer: A Multi-Cohort Transcriptomic Study

    Posted on Research Square on 22 September 2026; not peer reviewed; matched Atlas.

  10. Preprint· Research Square

    Beyond Conventional Nutritional Markers: Dynapenia and GLIM-Defined Malnutrition Represent Distinct Clinical Dimensions in Oncology Patients

    Posted on Research Square on 22 September 2026; not peer reviewed; matched MET.

  11. Preprint· bioRxiv

    Biomarker-Targeted O6-Guanine Alkylation Potentiates ATR Inhibitor Response in De Novo and Relapsed/Refractory AML

    Posted on bioRxiv on 22 September 2026; not peer reviewed; matched ATR.

  12. Preprint· bioRxiv

    Bispecific GD2xB7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma

    Posted on bioRxiv on 22 September 2026; not peer reviewed; matched GD2, Bispecific antibodies and Antibody-drug conjugate.

  13. Preprint· bioRxiv

    Catalytically inactive PARP1 protein drives PARP inhibitor induced hematological toxicity

    Posted on bioRxiv on 22 September 2026; not peer reviewed; matched PARP inhibitors, PARP and BRCA1 / BRCA2.

  14. Preprint· bioRxiv

    CD11c+ microglia promote dysfunctional T cell activation in diffuse midline glioma

    Posted on bioRxiv on 22 September 2026; not peer reviewed; matched CSF1R.

  15. Preprint· Research Square

    Cell-free DNA profiling for cancer detection and monitoring in dogs: a cross-study benchmark

    Posted on Research Square on 22 September 2026; not peer reviewed; matched Liquid biopsy.

  16. Preprint· bioRxiv

    Chronic Alcohol Exposure Induces Persistent DNA Damage Response Signaling and Sensitizes Breast Epithelial Cells to PARP Inhibition

    Posted on bioRxiv on 22 September 2026; not peer reviewed; matched PARP inhibitors, PARP and ATR.

  17. Preprint· Research Square

    Clinical quality of large language model answers to questions about pancreatic cancer

    Posted on Research Square on 22 September 2026; not peer reviewed; matched AI trial matching & clinical decision support and BioEmu.

  18. Preprint· Research Square

    Closing the Belief–Behaviour Gap in Cancer Screening: Evidence from a Population-Based Study in Two Polish Voivodeships

    Posted on Research Square on 22 September 2026; not peer reviewed; matched Chemoprevention & risk-reducing surgery.

17

  1. Paper· Blood Cancer Discov

    A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

    Published in Blood Cancer Discov on 21 September 2026; matched the OnCo record for Acute lymphoblastic leukaemia.

  2. Paper

    Androgens Drive SOX9 Upregulation in Injured Proximal Tubular Cells.

    Published on 21 September 2026 after first appearing as a preprint; matched Platinum agents and Androgen receptor.

  3. Paper· Muscle Nerve

    Assessment of Lectin Staining Biomarkers for GNE Myopathy Gene Therapy.

    Published in Muscle Nerve on 21 September 2026; matched the OnCo record for Small intestine cancer.

  4. Paper

    Code-multiplexed multi-frequency impedance cytometry with a unified deep-unfolding network.

    Published on 21 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.

  5. Paper· Pediatr Blood Cancer

    Comparative Effectiveness of Antibiotic Prophylaxis Regimens in Pediatric Acute Myeloid Leukemia.

    Published in Pediatr Blood Cancer on 21 September 2026; matched the OnCo record for Acute myeloid leukaemia in children.

  6. Paper

    Disease-state-themed escape room simulations in undergraduate pharmacy education: A systematic review.

    Published on 21 September 2026 after first appearing as a preprint; matched Med-Gemini and MedLM and State.

  7. Paper· Cancer Immunol Res

    IL-21 boosts T cell-therapy efficacy for solid tumors by enhancing mitochondrial Ca2+-mediated motility of effector CD8+ T cells.

    Published in Cancer Immunol Res on 21 September 2026; matched the OnCo record for TCR-T cell therapy.

  8. Paper· Signal Transduct Target Ther

    Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation.

    Published in Signal Transduct Target Ther on 21 September 2026; matched the OnCo record for Aumolertinib.

  9. Paper· Genet Test Mol Biomarkers

    Integrative Genetic and Bioinformatic Analysis of Androgen Pathway Gene Polymorphisms, Testosterone, and PSA Levels in Prostate Cancer.

    Published in Genet Test Mol Biomarkers on 21 September 2026; matched the OnCo record for CYP17A1.

  10. Paper

    Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Cancer.

    Published on 21 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.

  11. Issue· OnCo weekly issue

    OnCo weekly, 2026-09-21

    310 changelog entries, 1 upcoming date, 7 publications, 2 corrections.

  12. Paper· Arthritis Care Res (Hoboken)

    Real-world effectiveness and safety of secukinumab in giant cell arteritis: an Italian multicentre cohort study.

    Published in Arthritis Care Res (Hoboken) on 21 September 2026; matched the OnCo record for Tocilizumab.

  13. Paper· Adv Sci (Weinh)

    Ribonucleotides Amplify Mitochondrial DNA-Driven cGAS-STING Activation via FdUMP-ribonucleotide Hybrid Particles to Potentiate Chemoimmunotherapy.

    Published in Adv Sci (Weinh) on 21 September 2026; matched the OnCo record for Floxuridine.

  14. Paper· Clin Cancer Res

    Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study.

    Published in Clin Cancer Res on 21 September 2026; matched the OnCo record for Adavosertib.

  15. Paper· Br J Dermatol

    Sustained response (ORR4) as an on-treatment prognostic marker in mogamulizumab-treated mycosis fungoides and Sézary syndrome: the FIL-MOGA study.

    Published in Br J Dermatol on 21 September 2026; matched the OnCo record for Mogamulizumab.

  16. Paper· Head Neck

    Toripalimab Plus TPF as Induction Chemoimmunotherapy for the Treatment of Locally Advanced Hypopharyngeal Carcinoma: A Prospective Phase II Study.

    Published in Head Neck on 21 September 2026; matched the OnCo record for Toripalimab.

  17. Paper· Arthritis Rheumatol

    Treatment approaches to macrophage activation syndrome in real life and priorities for future research: results from the international METAPHOR project.

    Published in Arthritis Rheumatol on 21 September 2026; matched the OnCo record for Emapalumab.

13

  1. Paper· Lab Anim Res

    Advancing neurofibromatosis research: a comparative review of animal models and their utility in dissecting the tumor microenvironment.

    Published in Lab Anim Res on 20 September 2026; matched the OnCo record for Genetically engineered mouse models.

  2. Paper· Oncogene

    Beyond the blood-brain barrier: humanised mice, the missing link in glioblastoma research.

    Published in Oncogene on 20 September 2026; matched the OnCo record for Humanised mouse models.

  3. Paper· Cancer Causes Control

    Bridging the data latency gap: automated extraction of genomic biomarkers from unstructured clinical documents to support real-world oncology data.

    Published in Cancer Causes Control on 20 September 2026; matched the OnCo record for Oncotype DX.

  4. Paper· Crit Rev Oncol Hematol

    Current Management and Investigational Therapeutic Strategies in Penile Squamous Cell Carcinoma: A Narrative Review.

    Published in Crit Rev Oncol Hematol on 20 September 2026; matched the OnCo record for Penile cancer.

  5. Paper· Crit Rev Oncol Hematol

    Emerging Patterns of Kidney Cancer in Young Adults: Where Do We Stand? Emerging Patterns of Kidney Cancer in Young Adults: Where Do We Stand?

    Published in Crit Rev Oncol Hematol on 20 September 2026; matched the OnCo record for Belzutifan.

  6. Paper· Cardiovasc Toxicol

    Genetic and Molecular Determinants of Cancer Therapy-Related Cardiovascular Toxicity.

    Published in Cardiovasc Toxicol on 20 September 2026; matched the OnCo record for HER4.

  7. Paper· Br J Haematol

    Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.

    Published in Br J Haematol on 20 September 2026; matched the OnCo record for Acute lymphoblastic leukaemia.

  8. Paper· Acta Biomater

    Leukemic Stem Cell-Targeted Liposomal Nanoimmunotherapy Reverses Immune Evasion and Inhibits Fusion Oncoprotein-Driven Acute Myeloid Leukemia by Silencing B-Cell Lymphoma 2.

    Published in Acta Biomater on 20 September 2026; matched the OnCo record for CD123.

  9. Paper· Int J Cancer

    Longitudinal Associations of Oxaliplatin Treatment With Chemotherapy-Induced Peripheral Neuropathy in Colorectal cancer Survivors up to 2 Years Post-Treatment.

    Published in Int J Cancer on 20 September 2026; matched the OnCo record for CAPOX.

  10. Paper· Cancer Causes Control

    Predictors of perceived value of multi-cancer early detection testing: a national PRECEDE-PROCEED framework study.

    Published in Cancer Causes Control on 20 September 2026; matched the OnCo record for Multi-cancer early detection.

  11. Paper· Expert Opin Ther Pat

    Progress with FAK inhibitors in the patent literature (2020-present).

    Published in Expert Opin Ther Pat on 20 September 2026; matched the OnCo record for Avutometinib + defactinib.

  12. Paper· Future Oncol

    Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma.

    Published in Future Oncol on 20 September 2026; matched the OnCo record for Avelumab.

  13. Paper· Clin Med (Lond)

    Updates to contemporary care of glioblastoma.

    Published in Clin Med (Lond) on 20 September 2026; matched the OnCo record for Tumour treating fields.

25

  1. Paper

    <i>XIST</i> Is a Key Modulator Associated With the Adhesome Network.

    Published on 19 September 2026 after first appearing as a preprint; matched Atlas.

  2. Paper· Bioorg Chem

    A pyridone-fused imidazo[1,2-a]pyridine hybrid binds to tubulin at the vinblastine site, depolymerizes microtubules and inhibits Cancer cell proliferation.

    Published in Bioorg Chem on 19 September 2026; matched the OnCo record for Vinblastine.

  3. Paper· J Hematop

    Acute myeloid leukemia arising in treated chronic lymphocytic leukemia/small lymphocytic lymphoma: a challenge in analysis of lineage relationship.

    Published in J Hematop on 19 September 2026; matched the OnCo record for CD123.

  4. Paper

    ARID2 Loss Destabilizes PBAF and Drives Colorectal Cancer.

    Published on 19 September 2026 after first appearing as a preprint; matched STAT5.

  5. Paper· Curr Opin Oncol

    Beyond poly(ADP-ribose) polymerase inhibition: emerging therapeutic strategies for germline BRCA1/2-mutated and PALB2-mutated breast cancers.

    Published in Curr Opin Oncol on 19 September 2026; matched the OnCo record for Talazoparib.

  6. Paper· EJHaem

    Clinicopathologic Characteristics of Somatic <i>TP53</i> Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review.

    Published in EJHaem on 19 September 2026; matched the OnCo record for BCR::ABL1.

  7. Paper· Mol Ther

    Development of CRISPR_SCD001, an Autologous Hematopoietic Stem Cell Gene Therapy for Sickle Cell Disease after CRISPR-Cas9 Mediated Correction.

    Published in Mol Ther on 19 September 2026; matched the OnCo record for Plerixafor.

  8. Paper· BMJ Paediatr Open

    Distribution, socioeconomic inequalities and contributing factors of anaemia prevalence across wealth index among Indian adolescent girls: multivariate decomposition analysis of nationally representative survey.

    Published in BMJ Paediatr Open on 19 September 2026; matched the OnCo record for HB-200.

  9. Paper· Radiother Oncol

    Efficacy and safety of omitting the clinical target volume in limited-stage small cell lung cancer: a large-scale multicenter real-world study.

    Published in Radiother Oncol on 19 September 2026; matched the OnCo record for Limited-stage small-cell lung cancer.

  10. Paper

    Five-year outcomes of partial breast proton beam therapy without lumpectomy for early-stage breast cancer: an interventional prospective study.

    Published on 19 September 2026 after first appearing as a preprint; matched Estrogen receptor.

  11. Paper· Eur J Nucl Med Mol Imaging

    Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study.

    Published in Eur J Nucl Med Mol Imaging on 19 September 2026; matched the OnCo record for Gallium-68 gozetotide.

  12. Paper· Int J Surg Pathol

    Hepatocellular Carcinoma With a Grade 3 Neuroendocrine Tumor Component: A Case Report.

    Published in Int J Surg Pathol on 19 September 2026; matched the OnCo record for Grade 3 well-differentiated neuroendocrine tumour.

  13. Paper· Cell Death Discov

    Immunogenic cell death as a mechanism of synergy between sunitinib and <sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors.

    Published in Cell Death Discov on 19 September 2026; matched the OnCo record for Lutetium-177 dotatate.

  14. Paper· Biochem Pharmacol

    In vivo CAR‑T cell therapy: mechanisms, clinical advances and optimization strategies.

    Published in Biochem Pharmacol on 19 September 2026; matched the OnCo record for In vivo CAR-T.

  15. Paper· Libyan J Med

    Integrating immunophenotyping and morphology in the diagnosis of acute leukemia at the National Oncology Center, Sana'a, Yemen.

    Published in Libyan J Med on 19 September 2026; matched the OnCo record for Anal high-grade squamous intraepithelial lesions.

  16. Paper· Oral Oncol

    Investigating the impact of margins on the management of oropharyngeal cancer treated with transoral robotic surgery: a survey of head and neck oncologists' treatment patterns.

    Published in Oral Oncol on 19 September 2026; matched the OnCo record for Transoral robotic surgery.

  17. Paper· Biochem Pharmacol

    IRF1-driven chromatin and transcriptional regulation determines the anti-tumor responses to all-trans retinoic acid across cancer types.

    Published in Biochem Pharmacol on 19 September 2026; matched the OnCo record for Acute promyelocytic leukaemia.

  18. Paper· Cancer Metastasis Rev

    Precision therapeutic strategies for advanced gastrointestinal stromal tumors.

    Published in Cancer Metastasis Rev on 19 September 2026; matched the OnCo record for Ripretinib.

  19. Paper· Transplant Cell Ther

    Prognostic Associations of Molecular MRD and Genomic Features in ZNF384-Rearranged B-ALL Undergoing Allo-HSCT.

    Published in Transplant Cell Ther on 19 September 2026; matched the OnCo record for CD33.

  20. Paper· Clin Drug Investig

    Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA.

    Published in Clin Drug Investig on 19 September 2026; matched the OnCo record for Bendamustine.

  21. Paper· Int J Surg Pathol

    Salivary Duct Carcinoma With Rhabdoid and Signet-Ring Cell Features Mimicking Invasive Lobular Carcinoma of the Breast: A Case Report and Review of the Literature.

    Published in Int J Surg Pathol on 19 September 2026; matched the OnCo record for Salivary duct carcinoma.

  22. Paper· Int J Hematol

    Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes.

    Published in Int J Hematol on 19 September 2026; matched the OnCo record for Decitabine.

  23. Paper· Target Oncol

    Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

    Published in Target Oncol on 19 September 2026; matched the OnCo record for Tucatinib.

  24. Paper· Int J Clin Oncol

    Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study.

    Published in Int J Clin Oncol on 19 September 2026; matched the OnCo record for Amrubicin.

  25. Paper· J Robot Surg

    Transoral Robotic Surgery (TORS) versus radical radiotherapy following neoadjuvant therapy for oropharyngeal carcinoma: a multicenter, real-world efficacy and safety analysis.

    Published in J Robot Surg on 19 September 2026; matched the OnCo record for Transoral robotic surgery.

63

  1. Approval· FDA

    FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

    On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.

  2. Paper· J Clin Oncol

    Association Between Patient-Reported Outcomes and Health Care Resource Utilization: Toward Developing Patient-Centered Value Measures in Cancer Care.

    Published in J Clin Oncol on 18 September 2026; matched the OnCo record for Early-stage classical Hodgkin lymphoma.

  3. Paper· Cancer Discov

    Phase III Trials Test First-Line Options in Advanced NSCLC.

    Published in Cancer Discov on 18 September 2026; matched the OnCo record for Amivantamab.

  4. Paper· Cancer Cell

    γδ T cells modulate anti-tumor immunity in small cell lung cancer.

    Published in Cancer Cell on 18 September 2026; matched the OnCo record for Zoledronic acid.

  5. Paper· Oncol Rep

    [Corrigendum] The interaction between miR‑148a and DNMT1 suppresses cell migration and invasion by reactivating tumor suppressor genes in pancreatic cancer.

    Published in Oncol Rep on 18 September 2026; matched the OnCo record for DNMT1.

  6. Paper· Dermatologie (Heidelb)

    [Update on anal dysplasia and anal cancer].

    Published in Dermatologie (Heidelb) on 18 September 2026; matched the OnCo record for Metastatic and recurrent anal squamous cell carcinoma.

  7. Paper· Oncogene

    A canonical role of SMAD4 in safeguarding 3D genome architecture to suppress lung tumorigenesis.

    Published in Oncogene on 18 September 2026; matched the OnCo record for Genetically engineered mouse models.

  8. Paper· Mol Med Rep

    A four‑gene signature identifies TKI‑induced persister cells and uncovers a ZLN005‑induced pyroptotic vulnerability via the GSDME pathway in EGFR‑mutant lung cancer.

    Published in Mol Med Rep on 18 September 2026; matched the OnCo record for EGFR-mutated non-small-cell lung cancer.

  9. Paper· Br J Haematol

    A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial.

    Published in Br J Haematol on 18 September 2026; matched the OnCo record for Avelumab.

  10. Paper· Clin Oncol (R Coll Radiol)

    Acute Myocardial Infarction in Head and Neck Cancer Patients and Survivors: A Population-Based Cohort Study of Patient, Disease, and Treatment Factors.

    Published in Clin Oncol (R Coll Radiol) on 18 September 2026; matched the OnCo record for Hypopharyngeal cancer.

  11. Paper· Mol Cell Proteomics

    Anagrelide remodels the PDE3A-SLFN12 interactome to associate with translation initiation machinery in cancer cell lines.

    Published in Mol Cell Proteomics on 18 September 2026; matched the OnCo record for Anagrelide.

  12. Paper· J Clin Pathol

    Artificial Intelligence in Digital Pathology for Prostate Cancer Detection: FDA Clearance and Real-World Implementation.

    Published in J Clin Pathol on 18 September 2026; matched the OnCo record for Paige Prostate Detect.

  13. Paper· Spine J

    Beyond Anatomical Resectability: A Hypermetabolic and Highly Aggressive Subtype of Spinal Chordoma Associated with Cancer-Specific Progression.

    Published in Spine J on 18 September 2026; matched the OnCo record for Chordoma.

  14. Paper· BMJ Open

    Can early <sup>68</sup>Ga-PSMA-11 PET/CT predict 6-month disease control in patients receiving first-line systemic therapy for metastatic clear-cell renal cell carcinoma? Protocol for the multicentre prospective phase II PSMA-RENAL study in Belgium.

    Published in BMJ Open on 18 September 2026; matched the OnCo record for Gallium-68 gozetotide.

  15. Paper· Angew Chem Int Ed Engl

    Carbohydrate-Directed Labeling Probes for UV-Independent Chemoproteomic Profiling of Carbohydrate-Protein Interactions.

    Published in Angew Chem Int Ed Engl on 18 September 2026; matched the OnCo record for CD22.

  16. Paper· J Urol

    Chemotherapy Versus Surgery for Stage IIA Nonseminomatous Germ Cell Tumor: A Comparative Cost Utility Analysis.

    Published in J Urol on 18 September 2026; matched the OnCo record for Testicular germ cell tumours.

  17. Paper· Cell Rep Med

    Class visualizations and activation atlases for computational pathology.

    Published in Cell Rep Med on 18 September 2026; matched the OnCo record for Pathology & radiology foundation models.

  18. Paper· Int J Surg Pathol

    Claudin 18.2 Expression and Outcomes in Resected Gallbladder and Biliary Tract Adenocarcinomas: A Pilot Clinicopathologic Study.

    Published in Int J Surg Pathol on 18 September 2026; matched the OnCo record for VENTANA PD-L1 (SP263) Assay.

  19. Paper· Am J Clin Oncol

    Combination of Immune Checkpoint Inhibitors With Vascular Endothelial Growth Factor-Targeted Agents in Advanced Gastric and Gastroesophageal Adenocarcinoma: A Systematic Review and Meta-analysis.

    Published in Am J Clin Oncol on 18 September 2026; matched the OnCo record for Rivoceranib.

  20. Paper· Patient

    Communicating Change on Multi-item Patient-Reported Outcome Measures: What Were the Meaningful Changes in Physical Functioning Experienced by Patients on Vimseltinib in the MOTION Trial.

    Published in Patient on 18 September 2026; matched the OnCo record for Vimseltinib.

  21. Paper· J Am Acad Dermatol

    Community-Based Skin Cancer Screening and Follow-up Outcomes from a Statewide Outreach Program.

    Published in J Am Acad Dermatol on 18 September 2026; matched the OnCo record for Skin cancer screening.

  22. Paper· Cancer Res Commun

    Compartment-specific CD8 infiltration and disease-specific survival in resected ampullary adenocarcinoma.

    Published in Cancer Res Commun on 18 September 2026; matched the OnCo record for Ampullary cancer.

  23. Paper

    CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer.

    Published on 18 September 2026 after first appearing as a preprint; matched Nintedanib and Immune checkpoint inhibitors.

  24. Paper· BMJ Case Rep

    Disseminated <i>Fusarium</i> infection following cladribine chemotherapy for hairy-cell leukaemia.

    Published in BMJ Case Rep on 18 September 2026; matched the OnCo record for Cladribine.

  25. Paper· Ann Med

    Effect of transcutaneous auricular vagus nerve stimulation on postoperative gastrointestinal dysfunction in patients with gynecological abdominal or pelvic tumors: a study protocol for a prospective, single-center, randomized, controlled clinical trial.

    Published in Ann Med on 18 September 2026; matched the OnCo record for Stage III melanoma.

  26. Paper· Urol Oncol

    Efficacy and safety analysis of disitamab vedotin combined with immunotherapy as neoadjuvant treatment to promote conversion to bladder preservation in bladder cancer: A retrospective comparative study with the GC combined with immunotherapy regimen.

    Published in Urol Oncol on 18 September 2026; matched the OnCo record for Gemcitabine + cisplatin.

  27. Paper· J Neurooncol

    Efficacy and safety of proton radiotherapy for progressive or surgically unfavorable adult pilocytic astrocytoma: a single-center experience.

    Published in J Neurooncol on 18 September 2026; matched the OnCo record for Paediatric low-grade glioma.

  28. Paper· Curr Opin Oncol

    Emerging role of targeted therapy in drug-resistant epilepsy in patients with glioma.

    Published in Curr Opin Oncol on 18 September 2026; matched the OnCo record for Vorasidenib.

  29. Paper· Actas Dermosifiliogr

    Erythematous dorsal plaques in 6 patients with advanced T-cell lymphoma: a clinical variant of mogamulizumab-associated rash.

    Published in Actas Dermosifiliogr on 18 September 2026; matched the OnCo record for Mogamulizumab.

  30. Paper

    Evolutionary rescue model informs strategies for driving cancer cell populations to extinction.

    Published on 18 September 2026 after first appearing as a preprint; matched State.

  31. Paper· BMC Med Imaging

    FDG-PET/CT-based treatment response predicts recurrence and overall survival in locally advanced cervical cancer.

    Published in BMC Med Imaging on 18 September 2026; matched the OnCo record for Locally advanced cervical cancer.

  32. Paper· Phys Med

    Feasibility of prostate offline adaptive radiation therapy using iterative reconstructed CBCT to optimize the ART workflow.

    Published in Phys Med on 18 September 2026; matched the OnCo record for MR-guided adaptive radiotherapy.

  33. Paper· J Immunother Cancer

    Frailty of older patients is not reflected in the melanoma tumor microenvironment and treatment response to immune checkpoint blockade therapy.

    Published in J Immunother Cancer on 18 September 2026; matched the OnCo record for Imaging mass cytometry.

  34. Paper· J Immunother Cancer

    Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products.

    Published in J Immunother Cancer on 18 September 2026; matched the OnCo record for Ciltacabtagene autoleucel.

  35. Paper· J Comp Eff Res

    Indirect treatment comparison of odevixibat and maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome.

    Published in J Comp Eff Res on 18 September 2026; matched the OnCo record for Small intestine cancer.

  36. Paper· Blood Adv

    Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis.

    Published in Blood Adv on 18 September 2026; matched the OnCo record for Allogeneic stem cell transplantation.

  37. Paper

    Metabolic modulation of glioblastoma by dietary intervention: a systematic review.

    Published on 18 September 2026 after first appearing as a preprint; matched Bevacizumab, Bevacizumab and Anti-angiogenic therapy.

  38. Paper· Future Oncol

    MH-Penile-002: a phase II, prospective, single-arm trial of neoadjuvant anti-EGFR antibody-drug conjugate plus PD-1 inhibitor in penile cancer with challenging penile preservation or regional lymph node metastasis.

    Published in Future Oncol on 18 September 2026; matched the OnCo record for Node-positive and metastatic penile cancer.

  39. Paper· Structure

    Modulating pseudokinase conformation from the ATP-binding site.

    Published in Structure on 18 September 2026; matched the OnCo record for HER3.

  40. Paper· Curr Hematol Malig Rep

    Molecular Response, Event-Free Survival, and Treatment-Free Remission in Myeloproliferative Neoplasms: Update and Review with Insights from MPN Asia 2026.

    Published in Curr Hematol Malig Rep on 18 September 2026; matched the OnCo record for Ropeginterferon alfa-2b.

  41. Paper· Auris Nasus Larynx

    Molecular targeted therapy for thyroid cancer in Japan: Current status and future perspectives.

    Published in Auris Nasus Larynx on 18 September 2026; matched the OnCo record for Companion diagnostics.

  42. Paper· J Comput Assist Tomogr

    Multiparametric Whole-Body MRI Protocols in Contemporary Clinical Practice: Indications, Technical Considerations, and Emerging Applications.

    Published in J Comput Assist Tomogr on 18 September 2026; matched the OnCo record for Whole-body MRI.

  43. Paper· Mol Biol Rep

    NHSL3 knockout modulates sorafenib response, growth, and motility in hepatocellular carcinoma cell models.

    Published in Mol Biol Rep on 18 September 2026; matched the OnCo record for CRAF.

  44. Paper· Drug Resist Updat

    Nucleolar METTL16 drives ccRCC tumorigenesis and pazopanib resistance via translational activation of JAG1/Notch signaling pathway.

    Published in Drug Resist Updat on 18 September 2026; matched the OnCo record for Pazopanib.

  45. Issue· OnCo weekly issue

    OnCo weekly, 2026-09-18

    303 changelog entries, 1 upcoming date, 11 publications, 8 corrections.

  46. Paper· Asian J Androl

    Onvansertib-mediated PLK1 inhibition impairs spermatogenesis in the murine testis.

    Published in Asian J Androl on 18 September 2026; matched the OnCo record for Onvansertib.

  47. Paper· ACS Sens

    Optimizing the Hinge Length of Chimeric Antigen Receptor with a DdFP-Based Immunological Synapse Biosensor.

    Published in ACS Sens on 18 September 2026; matched the OnCo record for Mesothelin.

  48. Paper· Oncol Rep

    Pemetrexed increases BRCA1 protein stability and sensitizes TNBC cells to radiotherapy.

    Published in Oncol Rep on 18 September 2026; matched the OnCo record for Pemetrexed.

  49. Paper· J Enzyme Inhib Med Chem

    Phthalazine as a medically versatile polyheterocyclic core with underexplored anticancer potential.

    Published in J Enzyme Inhib Med Chem on 18 September 2026; matched the OnCo record for PARP.

  50. Paper· Cancer Lett

    Plasma cfDNA fragmentomics enables non-invasive detection and preoperative risk stratification of bladder cancer in a multicenter study.

    Published in Cancer Lett on 18 September 2026; matched the OnCo record for cfDNA fragmentomics.

  51. Paper· Diagnosis (Berl)

    Plasma signals of lung tumor promotion and the ubiquitous challenge of biomarker specificity.

    Published in Diagnosis (Berl) on 18 September 2026; matched the OnCo record for CEACAM5.

  52. Paper· Mol Cell Proteomics

    PRC2 loss in MPNST is accompanied by SWI/SNF complex rewiring and sensitization to SMARCA2/4 and BET inhibition in vivo.

    Published in Mol Cell Proteomics on 18 September 2026; matched the OnCo record for Malignant peripheral nerve sheath tumour.

  53. Paper· J Formos Med Assoc

    Pre-operative magnetic resonance imaging for evaluating depth of invasion in oral tongue cancer: Precision and predictive value.

    Published in J Formos Med Assoc on 18 September 2026; matched the OnCo record for Oral tongue and floor of mouth cancer.

  54. Paper

    Prevalence and penetrance of heritable retinoblastoma in two adult population cohorts: implications for genomic newborn screening.

    Published on 18 September 2026 after first appearing as a preprint; matched Whole-exome & whole-genome sequencing.

  55. Paper· J Geriatr Oncol

    Prognostic value of the Nice Cancer Ageing Survival (NCAS) score in older adults with cancer: A retrospective single institutional study.

    Published in J Geriatr Oncol on 18 September 2026; matched the OnCo record for Geriatric assessment.

  56. Paper· Ann Surg Oncol

    Recurrence Patterns of Resected Ampullary Adenocarcinoma and Implications for Multimodal Therapy: A Hidden Genome-Derived Analysis from the Ampullary Cancer Collaborative.

    Published in Ann Surg Oncol on 18 September 2026; matched the OnCo record for Ampullary cancer.

  57. Paper· Mol Genet Genomics

    Retraction Note: Buparlisib induces eukaryotic elongation factor-2 expression to cause treatment failure for lung cancer cells.

    Published in Mol Genet Genomics on 18 September 2026; matched the OnCo record for Elongation factor 2.

  58. Paper· Biochim Biophys Acta Gen Subj

    Retraction notice to "Smoothened-independent activation of hedgehog signaling by rearranged during transfection promotes neuroblastoma cell proliferation and tumor growth" [Biochim. Biophys. Acta (BBA) - Gen. Subj. 1860 (2016) 1961-1972].

    Published in Biochim Biophys Acta Gen Subj on 18 September 2026; matched the OnCo record for Smoothened.

  59. Paper· Curr Probl Cancer

    Salvage outcomes with teclistamab after BCMA-directed therapy failure in relapsed/refractory multiple myeloma: a systematic review and meta-analysis.

    Published in Curr Probl Cancer on 18 September 2026; matched the OnCo record for Teclistamab.

  60. Paper

    Somatic selection shapes mutation accumulation in Citrus sinensis.

    Published on 18 September 2026 after first appearing as a preprint; matched Cytarabine, Dacarbazine and Daunorubicin.

  61. Paper

    Sweet interference: oral fermentation volatile confounders in exhaled breath revealed by minimal glucose exposure.

    Published on 18 September 2026 after first appearing as a preprint; matched Decitabine + cedazuridine.

  62. Paper· Mol Cancer Ther

    Systematic Evaluation of Combination Strategies with Rezatapopt in p53 Y220C-Mutant Cancer Models.

    Published in Mol Cancer Ther on 18 September 2026; matched the OnCo record for MDM2 inhibitors.

  63. Paper· J Natl Compr Canc Netw

    Targeting KRAS-Mutant Lung Cancers.

    Published in J Natl Compr Canc Netw on 18 September 2026; matched the OnCo record for Adagrasib.

20

  1. Paper· Science

    An expert-level generalist AI for abdominal CT diagnosis.

    Published in Science on 17 September 2026; matched the OnCo record for RaDaR.

  2. Paper· Cancer Discov

    Anti-B7-H3 ADCs Take Center Stage against SCLC at WCLC.

    Published in Cancer Discov on 17 September 2026; matched the OnCo record for YL201.

  3. Paper· Nat Med

    Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma.

    Published in Nat Med on 17 September 2026; matched the OnCo record for Diffuse midline glioma, H3 K27-altered.

  4. Paper· Ann Oncol

    Navigating uncertainties and evidence gaps in adjuvant therapy for premenopausal women with HR+/HER2- breast cancer.

    Published in Ann Oncol on 17 September 2026; matched the OnCo record for Goserelin / leuprolide.

  5. Issue· OnCo weekly issue

    OnCo weekly, 2026-09-17

    147 changelog entries, 1 upcoming date, 14 publications, 91 corrections.

  6. Proposal· FDA

    Proposed approval: Givinostat

    openFDA has a label for "Givinostat".

  7. Proposal· EMA

    Proposed regional approval row: Alemtuzumab

    EMA register: MabCampath (alemtuzumab) Withdrawn, 2001-07-06.

  8. Proposal· EMA

    Proposed regional approval row: Anagrelide

    EMA register: Xagrid (anagrelide) Authorised, 2004-11-15.

  9. Proposal· EMA

    Proposed regional approval row: Aprepitant

    EMA register: Emend (aprepitant) Authorised, 2003-11-11.

  10. Proposal· EMA

    Proposed regional approval row: Bexarotene

    EMA register: Targretin (bexarotene) Authorised, 2001-03-29.

  11. Proposal· EMA

    Proposed regional approval row: Busulfan

    EMA register: Busilvex (busulfan) Withdrawn, 2003-07-09.

  12. Proposal· EMA

    Proposed regional approval row: Capecitabine

    EMA register: Xeloda (capecitabine) Authorised, 2001-02-02.

  13. Proposal· EMA

    Proposed regional approval row: Capmatinib

    EMA register: Tabrecta (capmatinib) Authorised, 2022-06-20.

  14. Proposal· EMA

    Proposed regional approval row: Carmustine

    EMA register: Carmustine medac (previously Carmustine Obvius) (carmustine) Authorised, 2018-07-18.

  15. Proposal· EMA

    Proposed regional approval row: Catumaxomab

    EMA register: Korjuny (catumaxomab) Authorised, 2025-02-10.

  16. Proposal· EMA

    Proposed regional approval row: Clofarabine

    EMA register: Evoltra (clofarabine) Authorised, 2006-05-29.

  17. Proposal· EMA

    Proposed regional approval row: Cytarabine

    EMA register: DepoCyte (cytarabine) Withdrawn, 2001-07-11.

  18. Proposal· EMA

    Proposed regional approval row: Dabrafenib

    EMA register: Tafinlar (dabrafenib) Authorised, 2013-08-26.

  19. Proposal· EMA

    Proposed regional approval row: Darbepoetin alfa

    EMA register: Aranesp (darbepoetin alfa) Authorised, 2001-06-08.

  20. Proposal· EMA

    Proposed regional approval row: Daunorubicin

    EMA register: Vyxeos liposomal (previously Vyxeos) (daunorubicin;cytarabine) Authorised, 2018-08-23.

3

  1. Paper· J Clin Oncol

    Bridging the Gap: From Molecular Residual Disease to Curative Opportunity: Circulating Tumor DNA-Guided Surveillance After Curative Resection for Stage I to III Colorectal Cancer.

    Published in J Clin Oncol on 16 September 2026; matched the OnCo record for Localised anal squamous cell carcinoma.

  2. Paper· Cancer Cell

    Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.

    Published in Cancer Cell on 16 September 2026; matched the OnCo record for Adebrelimab.

  3. Paper· J Clin Oncol

    Erratum: Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.

    Published in J Clin Oncol on 16 September 2026; matched the OnCo record for Trastuzumab rezetecan.

2

  1. Paper· Nature

    Author Correction: Erythropoietin receptor on cDC1s dictates immune tolerance.

    Published in Nature on 15 September 2026; matched the OnCo record for Erythropoietin receptor.

  2. Paper· Nat Med

    Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRAS<sup>G12D</sup> mutations: a phase 1 trial.

    Published in Nat Med on 15 September 2026; matched the OnCo record for GFH375.

2

  1. Paper· Nat Cancer

    Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial.

    Published in Nat Cancer on 14 September 2026; matched the OnCo record for FOLFIRI.

  2. Paper· J Clin Oncol

    P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in <i>EGFR</i>-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.

    Published in J Clin Oncol on 14 September 2026; matched the OnCo record for Afatinib.

1

  1. Paper· N Engl J Med

    Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.

    Published in N Engl J Med on 12 September 2026; matched the OnCo record for YL201.

1

  1. Approval· FDA

    FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer

    On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

2

  1. Approval· FDA

    Approval: Camizestrant (US)

    Accelerated approval (Etcamah).

  2. Approval· FDA

    FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer

    On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.

2

  1. Approval· FDA

    Approval: Daraxonrasib (US)

    NDA 220910 approved as Rasonque: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

  2. Approval· FDA

    FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma

    On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.

1

  1. Approval· FDA

    FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma

    On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra, BeOne Medicines USA, Inc.), as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.: dolutegravir.

1

  1. Approval· FDA

    FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

    On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

1

  1. Approval· FDA

    FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma

    On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

2

  1. Approval· FDA

    Approval: Amivantamab (US)

    Subcutaneous formulation (PALOMA-3).

    AmivantamabNon-small-cell lung cancerEGFR-mutated non-small-cell lung cancerMET exon 14 and MET-amplified non-small-cell lung cancerEGFRMETArteraAI BreastHR-positive / HER2-negative breast cancerAtezolizumabSmall-cell lung cancerHepatocellular carcinomaAdvanced hepatocellular carcinomaBladder & urothelial cancerBelantamab mafodotinMultiple myelomaRelapsed or refractory multiple myelomaBCMACemiplimabMelanomaPD-L1-high non-small-cell lung cancer without a driver mutationCutaneous squamous cell carcinomaAdvanced cutaneous squamous cell carcinomaDurvalumabBiliary tract cancerIntrahepatic cholangiocarcinomaExtrahepatic cholangiocarcinomaEncorafenibColorectal cancerBRAF V600E-mutant colorectal cancerBRAF V600E-mutant non-small-cell lung cancerLutetium-177 vipivotide tetraxetanProstate cancerMetastatic castration-resistant prostate cancerMetastatic hormone-sensitive prostate cancerPSMANivolumabRenal cell carcinomaHodgkin lymphomaOptune / Optune PaxGlioma & glioblastomaPancreatic ductal adenocarcinomaLocally advanced unresectable pancreatic ductal adenocarcinomaMesotheliomaPembrolizumabMismatch repair deficient (MSI-high) pancreatic ductal adenocarcinomaTriple-negative breast cancerHead and neck squamous cell carcinomaPiflufolastat F-18 / Pylarify TruVuRelacorilantOvarian cancerPlatinum-resistant ovarian cancerAdvanced and metastatic adrenocortical carcinomaRevumenibAcute myeloid leukaemiaAcute lymphoblastic leukaemiaNPM1-mutated and KMT2A-rearranged acute myeloid leukaemiaMeninSatricabtagene autoleucelGastric & gastro-oesophageal junction cancerClaudin 18.2TarlatamabExtensive-stage small-cell lung cancerLimited-stage small-cell lung cancerDLL3CD3TeclistamabTrastuzumab deruxtecanHER2-positive breast cancerHER2-positive gastric cancerVepdegestrantHR-positive metastatic breast cancer after CDK4/6 inhibitorsEstrogen receptorVusolimogene oderparepvecAdvanced melanomaZenocutuzumabKRAS wild-type pancreatic ductal adenocarcinomaHER2ZongertinibHER2-mutant non-small-cell lung cancer
  2. Approval· FDA

    FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer

    On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).

1

  1. Approval· FDA

    FDA approves zidesamtinib for ROS1 -positive non-small cell lung cancer

    On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).

2

  1. Approval· FDA

    FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

    On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.

  2. Approval· FDA

    FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

1

  1. Approval· FDA

    FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer

    On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC).

1

  1. Withdrawal· FDA

    Withdrawal: Zelenectide pevedotin (US)

    Programme deprioritised after regulatory feedback on Duravelo-2 design.

16

  1. Result· ClinicalTrials.gov

    A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor: Phase 3 result

    For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State: Arm A: Lazertinib With Amivantamab SC-CF 206 micrograms per milliliters (mcg/ml) versus Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion 144 micrograms per milliliters (mcg/ml).

  2. Result· ClinicalTrials.gov

    A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair: Phase 3 result

    Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator: BRCA Subgroup: Placebo With Abiraterone Acetate Plus Prednisone 25.99 months, hazard ratio 0.515.

  3. Result· ClinicalTrials.gov

    A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma: Phase 3 result

    Overall Survival (OS): Nofazinlimab + Lenvatinib 21.6 months versus Placebo + Lenvatinib 18.5 months.

  4. Result· ClinicalTrials.gov

    A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S: Phase 3 result

    Major Pathological Response (MPR) - IASLC Method: Osimertinib + Chemo 25.6 % versus Osimertinib 24.8 % versus Placebo + Chemo 1.7 %.

  5. Result· ClinicalTrials.gov

    A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma: Phase 3 result

    Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale: Nivo + Rela FDC SC 4.141 ug/ml versus Nivo + Rela FDC IV 3.901 ug/ml.

  6. Result· ClinicalTrials.gov

    A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance: Phase 3 result

    Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale: Nivolumab SC 77.373 μg/ml versus Nivolumab IV 36.875 μg/ml versus Nivo SC Process C 75.504 μg/ml versus Nivo SC Process D 75.596 μg/ml.

  7. Result· ClinicalTrials.gov

    A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer: Phase 3 result

    Progression Free Survival (PFS): Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 8.4 months versus Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 4.4 months, hazard ratio 0.43.

  8. Result· ClinicalTrials.gov

    A Study to Investigate Tolerability and Efficacy of Asciminib: Phase 3 result

    Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Interim Analysis): Asciminib 16 participants versus Nilotinib 34 participants, hazard ratio 0.45.

  9. Result· ClinicalTrials.gov

    An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi: Phase 3 result

    Red Blood Cell-transfusion Independence (RBC-TI) ≥ 12 Weeks (RBC-TI 12): Treatment 23.08 % versus Control 13.33 %.

  10. Result· onclive.com

    BL-B01D1-307: Phase 3 result

    PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).

  11. Result· cancernetwork.com

    CLARITY-Gastric 01: Phase 3 result

    Co-primary endpoints including OS met (July 2026); numbers pending.

  12. Result· amgen.com

    DeLLphi-305: Phase 3 result

    Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.

  13. Result· ClinicalTrials.gov

    DREAM3R: Phase 3 result

    Stopped early; primary endpoint not met.

  14. Result· ClinicalTrials.gov

    Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy: Phase 2/3 result

    Overall Survival (OS) (Arm A Versus Arm C): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 months versus Docetaxel (Arm C) 11.3 months, hazard ratio 0.85.

  15. Result· astrazeneca.com

    EMERALD-3: Phase 3 result

    PFS HR ~0.70 (interim); OS immature.

  16. Withdrawal· European Commission (EMA opinion)

    EU withdrawal: Duvelisib

    Marketing authorisation withdrawn in the European Union in 2026: Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons).

3

  1. Withdrawal· European Commission (EMA opinion)

    EU withdrawal: Cinacalcet

    Marketing authorisation withdrawn in the European Union in 2025: Mimpara: authorised 22 Oct 2004; marketing authorisation withdrawn 18 Dec 2025.

  2. Withdrawal· European Commission (EMA opinion)

    EU withdrawal: Lifileucel

    Marketing authorisation withdrawn in the European Union in 2025: MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing).

  3. Law· European Union, regulation

    European Health Data Space Regulation (EU) 2025/327

    A 2025 EU regulation that gives patients electronic access to their health records across the Union and creates national bodies that can grant researchers, regulators and companies permission to use anonymised or pseudonymised health data, phased in over the rest of the decade.

Sources

Everything above is read at build time from snapshots and records already in the repository; nothing is fetched when the page is viewed. Where each kind comes from and how often its source refreshes, from the workflow schedules in .github/workflows:

  • Approvals

    FDA Oncology Center of Excellence approval notifications (public/fda/recent.json), dated approvals recorded on product pages, and European Commission authorisations from the regional approvals table with an EPAR or regulator link.

    Refresh: FDA feed Wednesdays 06:07 UTC (refresh-fda.yml); EU rows checked against the EMA register Wednesdays 06:37 UTC (refresh-regional.yml); product pages by hand.

  • Withdrawals

    Dated withdrawals recorded on product pages and withdrawn EU authorisations in the regional approvals table, each with a source link.

    Refresh: Same schedule as approvals.

  • Results

    Trials in the corpus with a reported year and structured outcomes, linked to the primary paper, sponsor release or registry entry the outcome cites.

    Refresh: Curated by hand; ClinicalTrials.gov status refreshed Mondays 06:17 UTC (refresh-trials.yml).

  • Papers

    The newest Europe PMC matches for every product, target, cancer and technology (public/papers), journal versions of tracked preprints, and papers the roadmap watch found for landmark trials. One entry per DOI, however many records it matched.

    Refresh: Literature snapshot Tuesdays 05:41 UTC (refresh-papers.yml); roadmap watch Thursdays 05:29 UTC (roadmap-watch.yml).

  • Preprints

    bioRxiv, medRxiv, Research Square and other preprints of the last 90 days that match a target, product or technology query (public/preprints). Not peer reviewed.

    Refresh: Wednesdays 06:17 UTC (refresh-preprints.yml).

  • Law & policy

    Statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made, each linked to its primary text.

    Refresh: Curated by hand; new instruments are added when they are enacted.

  • Proposals

    Changes the nightly bot proposes for the corpus from the FDA feed, the EMA register and registry status changes (public/proposals/latest.json). Proposals, not facts: each waits for a human to apply it.

    Refresh: Daily 03:23 UTC (propose.yml).

  • Weekly issues

    OnCo's own weekly issue: what changed, regulatory events, upcoming readouts and what the journals published.

    Refresh: Mondays 07:31 UTC (newsletter.yml); the archive is rebuilt with every deploy.

Dates are shown at the precision the source gives: a year-only law or authorisation is grouped under its year, never given a day. Papers are matched to records by their literature queries, so a code or a common word can pull in an unrelated paper; the record chips tell you what matched. Not medical advice.